Gabapentin Tablet
Product Images NDC 71335-3060

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-3060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 01)

Chemical structure of gabapentin showing a cyclohexane ring with an amino group and a carboxyl group attached to the same carbon, representing the molecular structure of the active ingredient gabapentin.*

FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 02)

A line graph showing mean pain scores over 8 weeks comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain score from 0 to 10. Two periods are marked: a 4-week dose titration and a 4-week fixed dose. Gabapentin's pain scores decrease more than placebo over time.*

FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 03)

A line graph depicting mean pain scores over a 7-week period comparing Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including baseline, with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin groups indicate decreasing pain scores compared to placebo, which remains relatively stable.*

FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares placebo (PBO) and gabapentin (GBP) treatment groups across two studies. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg. Study 2 shows 14% response for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated by p-values (** p<0.01, *** p<0.001).*

FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 05)

A scatter plot chart depicting percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis with doses at 600, 900, 1200, and 1800 mg. Three studies are represented with different markers: Study a (black squares), Study b (gray squares), and Study c (white squares), showing data points clustered around varying difference percentages for each dose.*

FDA Label Image

Label (Lbl713353060)

Gabapentin Tablets, USP 600 mg oral tablets label showing 30 tablets per container. The label includes the NDC 71335-3060-1 and states the product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Graviti Pharmaceuticals Pvt. Ltd. It also provides storage instructions and a warning to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.